The U.S. Food and Drug Administration has granted accelerated approval to Sanofi’s Tzield® (teplizumab-mzwv) for children aged 8 to 17 years recently diagnosed with stage 3 type 1 diabetes (T1D), marking the drug’s first authorization as a disease-modifying therapy at this disease stage.
The approval is supported by data from the PROTECT Phase 3 study and clinical evidence gathered from over 900 patients across Sanofi’s global development program. Tzield works by modulating T-cells that drive the autoimmune destruction of insulin-producing pancreatic beta cells, aiming to slow that process from the point of initial diagnosis.
This approval builds on the drug’s April 2026 label expansion covering children as young as one year with stage 2 T1D, establishing a broader continuum of intervention across the diabetes spectrum.
Tzield carries a boxed warning for risk of serious viral infections, including Epstein-Barr virus and cytomegalovirus. Healthcare providers are advised to screen patients prior to initiation.
Written By: Sayan Das
Graphics by: Pramit Hazra
